Adults w/ wild-type RAS metastatic CRC (mCRC): 1st-line in combination w/ FOLFOX or FOLFIRI; 2nd-line in combination w/ FOLFIRI for patients who have received 1st-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Monotherapy after failure of fluoropyrimidine-, oxaliplatin- & irinotecan-containing chemotherapy regimens.
View Vectibix overdosage for action to be taken in the event of an overdose.
Contraindications
History of severe or life-threatening hypersensitivity reactions. Interstitial pneumonitis or pulmonary fibrosis. Combination w/ oxaliplatin-based chemotherapy when mutant RAS mCRC or RAS status is unknown.
Hypersensitivity; infusion-related reactions. Not to be administered as IV push or bolus. Withhold or discontinue if dermatologic or soft tissue toxicity associated w/ severe or life-threatening inflammatory or infectious complications occurs. Acute onset or worsening pulmonary symptoms, history of interstitial pneumonitis or pulmonary fibrosis; severe diarrhoea & dehydration; history of keratitis, ulcerative keratitis or severe dry eye. Assess patients w/ ECOG 2 performance status prior to treatment. Monitor for inflammatory or infectious sequelae development; hypomagnesemia & accompanying hypocalcemia & electrolytes prior to, during & up to 8 wk after therapy. Contact lens users. Limit sun exposure. May affect ability to drive & use machines. Not to be used w/ bevacizumab-containing chemotherapy. Avoid combination w/ IFL. Acute renal failure. Renal or hepatic impairment. May affect female fertility. Women of childbearing potential should use effective contraception during & for 2 mth after last dose. Pregnancy. Not to be used during lactation. Elderly ≥65 yr.
Sign Out
